Saxenda (liraglutide 3 mg) UK research guide 2026

What is Saxenda?

Saxenda is Novo Nordisk's proprietary brand of liraglutide at the 3 mg daily dose, licensed in the UK for chronic weight management. It was the first injectable GLP-1 receptor agonist to receive MHRA approval specifically for obesity rather than diabetes, and remains the only licensed once-daily GLP-1 option for weight management in the UK. Saxenda differs from Novo Nordisk's diabetes brand Victoza — which contains the same molecule at up to 1.8 mg daily — in both its dose and its licensed indication. The 3 mg daily dose in Saxenda produces greater central satiety signalling than the diabetes dose but also a higher incidence of gastrointestinal adverse effects.

UK regulatory status

Saxenda holds a full MHRA marketing authorisation for chronic weight management in adults with an initial BMI of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity. It is used as an adjunct to a reduced-calorie diet and increased physical activity. NICE technology appraisal TA664 (2020) recommended Saxenda for NHS use in England within specialist weight-management services, subject to eligibility criteria and a maximum treatment duration of two years, or until treatment response criteria are met. Private prescription is available from licensed UK clinicians without NHS referral. No significant supply disruptions have affected Saxenda in the UK in recent years; the semaglutide shortage that affected Ozempic and Wegovy between 2022 and 2024 did not extend to liraglutide, which is manufactured via a different process and has separate supply chains.

Clinical evidence summary

The pivotal evidence base for Saxenda is the SCALE programme. SCALE Obesity and Prediabetes (n = 3,731 adults without diabetes) demonstrated a mean weight reduction of approximately 8.0% with liraglutide 3 mg at 56 weeks versus 2.6% for placebo — the largest randomised weight-management trial at the time of its publication. Approximately 63.2% of participants in the active arm achieved at least 5% weight loss versus 27.1% on placebo. SCALE Diabetes (patients with type 2 diabetes) showed mean weight reduction of 6.0% at 56 weeks, consistent with the blunting effect of diabetes on GLP-1-driven weight loss. SCALE Maintenance evaluated liraglutide after an initial low-calorie diet phase and demonstrated superior weight maintenance versus placebo over 56 weeks. SCALE Sleep Apnoea demonstrated significant reductions in the apnoea–hypopnoea index (AHI) in patients with moderate-to-severe obstructive sleep apnoea. The cardiovascular outcomes data from the Victoza programme (LEADER trial, published 2016) showed a 13% reduction in MACE with liraglutide 1.8 mg in patients with type 2 diabetes and high cardiovascular risk, providing class-level cardiovascular safety evidence.

Mechanism

Liraglutide is a GLP-1 receptor agonist with 97% structural homology to human GLP-1, modified with a C16 fatty-acid side chain that enables albumin binding and extends its half-life to approximately 13 hours — sufficient for once-daily dosing but not for the weekly frequency achieved by semaglutide or tirzepatide. At the 3 mg dose in Saxenda, central hypothalamic GLP-1 receptor activation drives appetite suppression that extends beyond the glycaemic effects seen at lower diabetes doses. For the full mechanistic profile, see the liraglutide molecule page.

Dosing and administration

Saxenda is administered by subcutaneous injection once daily at any time of day, independently of meals. The titration schedule escalates the dose weekly: 0.6 mg daily in week 1; 1.2 mg daily in week 2; 1.8 mg daily in week 3; 2.4 mg daily in week 4; and 3.0 mg daily from week 5 as the full maintenance dose. The weekly titration is intended to reduce the severity of gastrointestinal side effects during initiation. If the 3.0 mg maintenance dose is not tolerated, dose reduction to 2.4 mg daily may be considered, though efficacy data supports the 3.0 mg dose. Injection sites include the abdomen, thigh, or upper arm; sites should be rotated.

Common side effects

Saxenda's side-effect profile is typical of the GLP-1 class, with gastrointestinal effects predominating. In SCALE Obesity and Prediabetes, nausea affected approximately 32.3% of participants on active treatment, diarrhoea 17.2%, vomiting 15.7%, and constipation 19.3%. Effects are most pronounced during the first four to eight weeks of dose titration and generally improve at a stable maintenance dose. Discontinuation due to adverse events occurred in approximately 9.9% of the liraglutide arm versus 3.8% for placebo. The daily injection schedule, combined with gastrointestinal tolerability challenges during titration, contributes to a higher discontinuation rate compared with once-weekly alternatives.

Saxenda vs alternative brands

Saxenda is the established first-generation injectable GLP-1 option for weight management in the UK, predating the more potent weekly options now available.

See also: Wegovy brand guide · Mounjaro brand guide · Ozempic brand guide.

Procurement and supplier position

This page is educational and does not advertise, sell, supply, recommend or rank any supplier, compounder, online pharmacy or telehealth service for Saxenda or any version of liraglutide. Saxenda is a UK prescription-only medicine and should only be accessed through a qualified UK prescriber following appropriate clinical assessment. See UK POM context for GLP-1 medicines.

Frequently asked questions

Is Saxenda available on the NHS?

Saxenda has been recommended by NICE for use within NHS specialist weight-management services in England (technology appraisal TA664, 2020). Eligibility criteria include a BMI ≥35 kg/m² with at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in specific circumstances. NHS prescribing is via Tier 3 or Tier 4 services; private prescription is available from licensed UK clinicians.

How is Saxenda different from Victoza?

Both Saxenda and Victoza contain liraglutide from Novo Nordisk, but at different doses and for different indications. Victoza delivers up to 1.8 mg liraglutide daily and is licensed for type 2 diabetes. Saxenda delivers up to 3.0 mg daily and is licensed for weight management. The higher dose in Saxenda produces more pronounced satiety signalling and greater weight reduction, but also a higher incidence of gastrointestinal side effects.

Is Saxenda as effective as Wegovy or Mounjaro?

Based on clinical trial data, Saxenda produces more modest weight reduction than either Wegovy or Mounjaro. SCALE Obesity and Prediabetes showed approximately 8% mean weight reduction with liraglutide 3 mg versus placebo at 56 weeks, compared with approximately 14.9% for Wegovy (STEP-1) and 20.9% for Mounjaro 15 mg (SURMOUNT-1). However, head-to-head trials between these agents in the same population are limited.

Why does Saxenda require daily injections when Wegovy and Mounjaro are weekly?

Liraglutide has a shorter half-life than semaglutide or tirzepatide. Liraglutide binds albumin less tightly and is cleared more rapidly (half-life approximately 13 hours), requiring daily administration. Semaglutide and tirzepatide both incorporate fatty-diacid side chains designed to achieve tighter albumin binding and half-lives of approximately 7 and 5 days respectively, enabling weekly dosing.

What does Saxenda contain?

Each Saxenda prefilled multi-dose pen contains liraglutide — a GLP-1 receptor agonist with 97% sequence homology to human GLP-1, modified to include a C16 fatty-acid side chain via a glutamic acid spacer to facilitate albumin binding and extend the half-life from minutes (for native GLP-1) to approximately 13 hours. It is administered daily by subcutaneous injection.

Can Saxenda be prescribed for type 2 diabetes?

No — in the UK, the diabetes-licensed liraglutide product is Victoza (up to 1.8 mg daily), not Saxenda. Saxenda is licensed only for weight management. Patients who have both type 2 diabetes and obesity are typically managed with Ozempic or Mounjaro, which carry indications for both conditions.